Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
| Autor: | Jia Zhe Su, Michael H. Malim, Daniel Cox, Neophytos Kouphou, Sam Acors, Carl Graham, Ana Maria Ortega-Prieto, Luke B Snell, Cassandra Fairhead, Stuart J. D. Neil, Liane Dupont, Helena Winstone, Thomas Lechmere, Rui Pedro Galão, Sadie R. Hallett, Gaia Nebbia, Isabella Huettner, Nathalia Almeida, Marie Jose Lista, Adela Alcolea-Medina, Thomas J. A. Maguire, Suzanne Pickering, Manu Shankar-Hari, Rahul Batra, Jonathan D. Edgeworth, Jose M. Jimenez-Guardeño, Katie J. Doores, Ruth E Dickenson, Jeffrey Seow, Themoula Charalampous, Harry Wilson, Blair Merrick |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
Adult Male COVID-19 Vaccines Immunology Alpha (ethology) Applied Microbiology and Biotechnology Microbiology Neutralization Immunoglobulin G Virus Article 03 medical and health sciences Young Adult 0302 clinical medicine Antibodies Viral/blood Neutralization Tests SARS-CoV-2/genetics Genetics Humans Neutralizing antibody Antibodies Neutralizing/blood 030304 developmental biology Aged Aged 80 and over 0303 health sciences biology SARS-CoV-2 Vaccination Immunization Passive Cell Biology Middle Aged Virology 3. Good health COVID-19/immunology Spike Glycoprotein Coronavirus/genetics Immunoglobulin M Viral infection Mutation biology.protein Female Antibody 030217 neurology & neurosurgery |
| Zdroj: | Nature Microbiology Dupont, L, Snell, L B, Graham, C, Seow, J, Merrick, B, Lechmere, T, Maguire, T J A, Hallett, S R, Pickering, S, Charalampous, T, Alcolea-Medina, A, Huettner, I, Jimenez-Guardeño, J M, Acors, S, Almeida, N, Cox, D, Dickenson, R E, Galao, R P, Kouphou, N, Lista, M J, Ortega-Prieto, A M, Wilson, H, Winstone, H, Fairhead, C, Su, J Z, Nebbia, G, Batra, R, Neil, S, Shankar-Hari, M, Edgeworth, J D, Malim, M H & Doores, K J 2021, ' Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern ', Nature Microbiology, vol. 6, no. 11, pp. 1433-1442 . https://doi.org/10.1038/s41564-021-00974-0 |
| ISSN: | 2058-5276 |
| DOI: | 10.1038/s41564-021-00974-0 |
| Popis: | COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of convalescent sera provide unique insights into antibody longevity and cross-neutralizing activity induced by variant spike proteins, which are putative vaccine candidates. Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta). Over time, despite a reduction in overall neutralization activity, differences in sera neutralization potency against SARS-CoV-2 and the Alpha and Beta variants decreased, which suggests that continued antibody maturation improves tolerance to spike mutations. We also compared the cross-neutralizing activity of wave 1 sera with sera from individuals infected with the Alpha, the Beta or the B.1.617.2 (Delta) variants up to 79 days post onset of symptoms. While these sera neutralize the infecting VOC and parental virus to similar levels, cross-neutralization of different SARS-CoV-2 VOC lineages is reduced. These findings will inform the optimization of vaccines to protect against SARS-CoV-2 variants. The authors assess the durability and long-term cross-reactivity of neutralizing antibodies raised in response to infections with SARS-CoV-2 or variants of concern in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink